What are the latest clinical trials for Multiple Myeloma in 2026

Latest Clinical Trials for Multiple Myeloma in 2026

I appreciate your question about the latest clinical trials. However, I need to be transparent about what I can tell you based on the current evidence available to me.

What I Can Share

According to the NCCN Guidelines for Patients: Multiple Myeloma (2025), clinical trials remain an important treatment option for people with multiple myeloma. The guidelines specifically recommend considering clinical trials as part of your treatment planning, particularly:

• For newly diagnosed myeloma – Clinical trials may offer newer drug combinations or approaches
• For relapsed or resistant myeloma – Trials are especially valuable when standard treatments stop working
• For emerging therapies – Including newer CAR T-cell therapies and bispecific antibodies

Recent Treatment Advances (As of 2025)

The NCCN Guidelines highlight several newer treatment approaches that are now available or in trials:

1. Bispecific Antibodies – Drugs like elranatamab (Elrexfio), talquetamab (Talvey), and teclistamab (Tecvayli) that bring T cells directly to myeloma cells
2. CAR T-cell Therapy – Including idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti)
3. Next-generation Proteasome Inhibitors and Immunomodulators – Newer combinations being tested

How to Find 2026 Clinical Trials

I cannot provide specific 2026 trial information because:

• Trial data changes frequently (new trials open, others close)
• My information has a knowledge cutoff
• Trial eligibility and locations vary by individual

Here's where to find current trials:

✅ ClinicalTrials.gov – Search "multiple myeloma" and filter by:

• Status: "Recruiting" or "Active, not recruiting"
• Location: Your state/region
• Phase: I, II, or III

✅ NCCN Member Institutions – Cancer centers affiliated with NCCN often have access to cutting-edge trials

✅ Your Oncology Team – They can identify trials matching YOUR specific myeloma characteristics (stage, biomarkers, prior treatments)

✅ Leukemia & Lymphoma Society – Offers trial-matching resources specifically for blood cancers

Questions to Ask Your Care Team About Trials

• Are there any clinical trials available for my specific type of myeloma?
• What are the eligibility requirements, and do I qualify?
• What are the potential benefits and risks compared to standard treatment?
• How often would I need to visit the trial site?
• What happens to my care if I need to leave the trial?
• Are there costs, or is the trial treatment provided?

Key Point

According to NCCN Guidelines, participating in a clinical trial is a legitimate treatment option that should be discussed alongside standard therapies. Trials often provide access to newer medications before they're widely available, and you receive close monitoring from the research team.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about clinical trial participation.